Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002299
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus CMV of the Eyes in Patients With AIDS
Sponsor:
Hoffmann-La Roche
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Combination Therapy With 9-13-Dihydroxy-2-Propoxymethyl Guanine DHPG and Interferon Beta for the Prevention of Relapse of Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome
Status:
COMPLETED
Status Verified Date:
1990-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of ganciclovir DHPG in combination with interferon beta to prevent relapse of cytomegalovirus retinitis in patients with AIDS While early clinical trials have shown that 30 mgkgweek of DHPG is usually sufficient to delay or prevent relapse neutropenia is a common dose-limiting problem in about 50 percent of patients Since in vitro data have suggested that there is synergism between DHPG and interferon beta against cytomegalovirus a reduced dose of DHPG in combination with a low dose of interferon beta may prevent relapse without causing neutropenia If remission can be maintained with low-dose DHPG and interferon beta maintenance therapy with a moderate dose of interferon beta alone will be evaluated in a subsequent protocol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ICM 1285 | None | None | None |